Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.

Kyrtsonis, M C; Kokoris, S I; Kontopidou, F N; Siakantaris, M P; Kittas, C; Pangalis, G A

Kyrtsonis, M C; Kokoris, S I; Kontopidou, F N; Siakantaris, M P; Kittas, C; Pangalis, G A.

Blood ; 97(8): 2527-8, 2001 Apr 15.

Article in En | MEDLINE | ID: mdl-11307775

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antigens, CD20/immunology; Antineoplastic Agents/adverse effects; Monoclonal Gammopathy of Undetermined Significance/therapy; Myeloproliferative Disorders/chemically induced; Thalidomide/adverse effects; Thrombocytosis/chemically induced; Waldenstrom Macroglobulinemia/etiology; Aged; Antibodies, Monoclonal/immunology; Antineoplastic Agents/therapeutic use; Disease Progression; Humans; Immunization, Passive; Immunoglobulin M/blood; Immunoglobulin kappa-Chains/blood; Male; Monoclonal Gammopathy of Undetermined Significance/drug therapy; Monoclonal Gammopathy of Undetermined Significance/metabolism; Paraproteins/analysis; Thalidomide/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Thrombocytosis / Monoclonal Gammopathy of Undetermined Significance / Waldenstrom Macroglobulinemia / Antigens, CD20 / Antibodies, Monoclonal / Myeloproliferative Disorders / Antineoplastic Agents Limits: Aged / Humans / Male Language: En Journal: Blood Year: 2001 Document type: Article

Search on Google

XML

PubMed Links